Verici Dx Past Earnings Performance
Past criteria checks 0/6
Verici Dx's earnings have been declining at an average annual rate of -2.3%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-2.3%
Earnings growth rate
9.7%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | n/a |
| Return on equity | -167.7% |
| Net Margin | -59,015.8% |
| Last Earnings Update | 30 Jun 2023 |
Revenue & Expenses BreakdownBeta
How Verici Dx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -11 | 10 | 0 |
| 31 Mar 23 | 0 | -11 | 10 | 0 |
| 31 Dec 22 | 0 | -11 | 10 | 0 |
| 30 Sep 22 | 0 | -11 | 10 | 0 |
| 30 Jun 22 | 0 | -11 | 10 | 0 |
| 31 Mar 22 | 0 | -10 | 8 | 0 |
| 31 Dec 21 | 0 | -8 | 7 | 0 |
Quality Earnings: VRCI is currently unprofitable.
Growing Profit Margin: VRCI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VRCI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare VRCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VRCI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: VRCI has a negative Return on Equity (-167.66%), as it is currently unprofitable.